Income Statement Presentation 2023

Hemophilia A: Hemlibra, new global standard of care 36% US/EU-5 patient share reached CHFM 1,200 1,000 800 +45% 600 +313% 400 200 +38% Roche YoY CER growth +24% • Q4 update • >19,000 patients treated globally Hemlibra continues to penetrate across all approved patient segments ⚫ Ph III (HAVEN 7) in infants (0-1 year) interim data presented at ASH 2022 • ⚫ SPK 8011 (hem A gene therapy) 5-year data with stable Factor VIII levels presented at ASH 2022 Outlook 2023 • EU: Label extension to include moderate patients (HAVEN 6) granted in Q1 • • US/EU: Further patient share gains in non-inhibitors • SPK 8011 pivotal Ph III to be initiated 0 Q4 19 Q4 20 Q4 21 Q4 22 US Europe International Japan CER-Constant Exchange Rates 27

View entire presentation